Compass Therapeutics Shares Surge on Promising Cancer Drug Data

Impressive Scientific Findings Drive Investor Confidence

Compass Therapeutics is experiencing significant pre-market trading activity today following the release of encouraging preclinical results for its oncology candidate CTX-10726. The biopharmaceutical company also confirmed it remains on track to submit its Investigational New Drug application during the fourth quarter of 2025.

Recent data presented at the SITC Annual Meeting demonstrates compelling evidence for CTX-10726, a bispecific antibody targeting both PD-1 and VEGF-A. The research reveals several key advantages:
– Strong binding affinity to both VEGF-A and PD-1 targets
– Effective disruption of receptor interactions
– Superior anti-tumor activity compared to existing therapeutic options
– Positive outcomes in human models of lung and colorectal cancers